lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway

Weidong Pan, Wen Li, Jun Zhao, Zhiyi Huang, Jingyuan Zhao, Shuxian Chen, Chusi Wang, Youqiu Xue, Feng Huang, Qiannan Fang, Julie Wang, David Brand, Song Guo Zheng

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) is a malignancy with one of the worst prognoses. Long noncoding RNA (lncRNA) are emerging as an important regulator of gene expression and function, leading to the development of cancer. The aim of this study was to determine the relationship between lncRNA and HCC and to further guide clinical therapy. lncRNA in HCC and adjacent tissues were screened, and the correlation between lncRNA-PDPK2P expression in liver tissues and the pathological characteristics and severity of HCC was assessed. The effects of PDPK2P on HCC proliferation, apoptosis, metastasis, and invasion were also systematically investigated via CCK-8 assay, flow cytometry, scratch wound healing, and transwell assay, respectively. The relationship between PDPK2P and PDK1 was verified by RNA pull-down, rescue experiments and western blot. lncRNA-PDPK2P was highly expressed in HCC tissues with a distinct positive correlation between PDPK2P and PDK1, and the upregulation was clinically associated with a larger tumor embolus, low differentiation, and poor survival. Mechanistically, lncRNA-PDPK2P interacted with PDK1 and promoted HCC progression through the PDK1/AKT/caspase 3 signaling pathway. lncRNA-PDPK2P can promote HCC progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis, and therapy of hepatocellular carcinoma.

Original languageEnglish (US)
JournalMolecular Oncology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Long Noncoding RNA
Caspase 3
Hepatocellular Carcinoma
Sincalide
Neoplasms
Regulator Genes
Embolism
Wound Healing
Flow Cytometry
Up-Regulation
Biomarkers
Western Blotting
RNA
Apoptosis
Neoplasm Metastasis
Gene Expression

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. / Pan, Weidong; Li, Wen; Zhao, Jun; Huang, Zhiyi; Zhao, Jingyuan; Chen, Shuxian; Wang, Chusi; Xue, Youqiu; Huang, Feng; Fang, Qiannan; Wang, Julie; Brand, David; Zheng, Song Guo.

In: Molecular Oncology, 01.01.2019.

Research output: Contribution to journalArticle

Pan, W, Li, W, Zhao, J, Huang, Z, Zhao, J, Chen, S, Wang, C, Xue, Y, Huang, F, Fang, Q, Wang, J, Brand, D & Zheng, SG 2019, 'lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway', Molecular Oncology. https://doi.org/10.1002/1878-0261.12553
Pan, Weidong ; Li, Wen ; Zhao, Jun ; Huang, Zhiyi ; Zhao, Jingyuan ; Chen, Shuxian ; Wang, Chusi ; Xue, Youqiu ; Huang, Feng ; Fang, Qiannan ; Wang, Julie ; Brand, David ; Zheng, Song Guo. / lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway. In: Molecular Oncology. 2019.
@article{d7e439d237b5477db213e62ee7d5e540,
title = "lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway",
abstract = "Hepatocellular carcinoma (HCC) is a malignancy with one of the worst prognoses. Long noncoding RNA (lncRNA) are emerging as an important regulator of gene expression and function, leading to the development of cancer. The aim of this study was to determine the relationship between lncRNA and HCC and to further guide clinical therapy. lncRNA in HCC and adjacent tissues were screened, and the correlation between lncRNA-PDPK2P expression in liver tissues and the pathological characteristics and severity of HCC was assessed. The effects of PDPK2P on HCC proliferation, apoptosis, metastasis, and invasion were also systematically investigated via CCK-8 assay, flow cytometry, scratch wound healing, and transwell assay, respectively. The relationship between PDPK2P and PDK1 was verified by RNA pull-down, rescue experiments and western blot. lncRNA-PDPK2P was highly expressed in HCC tissues with a distinct positive correlation between PDPK2P and PDK1, and the upregulation was clinically associated with a larger tumor embolus, low differentiation, and poor survival. Mechanistically, lncRNA-PDPK2P interacted with PDK1 and promoted HCC progression through the PDK1/AKT/caspase 3 signaling pathway. lncRNA-PDPK2P can promote HCC progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis, and therapy of hepatocellular carcinoma.",
author = "Weidong Pan and Wen Li and Jun Zhao and Zhiyi Huang and Jingyuan Zhao and Shuxian Chen and Chusi Wang and Youqiu Xue and Feng Huang and Qiannan Fang and Julie Wang and David Brand and Zheng, {Song Guo}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/1878-0261.12553",
language = "English (US)",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",

}

TY - JOUR

T1 - lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway

AU - Pan, Weidong

AU - Li, Wen

AU - Zhao, Jun

AU - Huang, Zhiyi

AU - Zhao, Jingyuan

AU - Chen, Shuxian

AU - Wang, Chusi

AU - Xue, Youqiu

AU - Huang, Feng

AU - Fang, Qiannan

AU - Wang, Julie

AU - Brand, David

AU - Zheng, Song Guo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hepatocellular carcinoma (HCC) is a malignancy with one of the worst prognoses. Long noncoding RNA (lncRNA) are emerging as an important regulator of gene expression and function, leading to the development of cancer. The aim of this study was to determine the relationship between lncRNA and HCC and to further guide clinical therapy. lncRNA in HCC and adjacent tissues were screened, and the correlation between lncRNA-PDPK2P expression in liver tissues and the pathological characteristics and severity of HCC was assessed. The effects of PDPK2P on HCC proliferation, apoptosis, metastasis, and invasion were also systematically investigated via CCK-8 assay, flow cytometry, scratch wound healing, and transwell assay, respectively. The relationship between PDPK2P and PDK1 was verified by RNA pull-down, rescue experiments and western blot. lncRNA-PDPK2P was highly expressed in HCC tissues with a distinct positive correlation between PDPK2P and PDK1, and the upregulation was clinically associated with a larger tumor embolus, low differentiation, and poor survival. Mechanistically, lncRNA-PDPK2P interacted with PDK1 and promoted HCC progression through the PDK1/AKT/caspase 3 signaling pathway. lncRNA-PDPK2P can promote HCC progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis, and therapy of hepatocellular carcinoma.

AB - Hepatocellular carcinoma (HCC) is a malignancy with one of the worst prognoses. Long noncoding RNA (lncRNA) are emerging as an important regulator of gene expression and function, leading to the development of cancer. The aim of this study was to determine the relationship between lncRNA and HCC and to further guide clinical therapy. lncRNA in HCC and adjacent tissues were screened, and the correlation between lncRNA-PDPK2P expression in liver tissues and the pathological characteristics and severity of HCC was assessed. The effects of PDPK2P on HCC proliferation, apoptosis, metastasis, and invasion were also systematically investigated via CCK-8 assay, flow cytometry, scratch wound healing, and transwell assay, respectively. The relationship between PDPK2P and PDK1 was verified by RNA pull-down, rescue experiments and western blot. lncRNA-PDPK2P was highly expressed in HCC tissues with a distinct positive correlation between PDPK2P and PDK1, and the upregulation was clinically associated with a larger tumor embolus, low differentiation, and poor survival. Mechanistically, lncRNA-PDPK2P interacted with PDK1 and promoted HCC progression through the PDK1/AKT/caspase 3 signaling pathway. lncRNA-PDPK2P can promote HCC progression, suggesting it may be a clinically valuable biomarker and serve as a molecular target for the diagnosis, prognosis, and therapy of hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85071295334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071295334&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12553

DO - 10.1002/1878-0261.12553

M3 - Article

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

ER -